openPR Logo
Press release

DNDi: PowerFolder increases investment in E-Health

04-06-2016 01:13 PM CET | IT, New Media & Software

Press release from: PowerFolder

PowerFolder deepens its - since 2014 existing - cooperation with the Drugs for Neglected Diseases initiative (DNDi) and donated additional PowerFolder licenses to the non-profit-organization, which fights neglected diseases. Pascal Carpentier, Head of Information Systems and Technology of DNDi: „We are very satisfied with PowerFolder and are excited to plan new applications.“

Meerbusch/Geneva, 06.04.2016 - The German company dal33t GmbH from Meerbusch, which is specialized in Sync & Share Solutions, donated an additional set of PowerFolder Enterprise licenses to the Drugs for Neglected Diseases initiative (DNDi). Thus, the since 2014 existing cooperation of the cloud specialist with the non-profit organization from the healthcare sector will be further expanded. The additional licenses are rapidly needed by DNDi, especially for new studies in the Democratic Republic of the Congo (DRC), to add more clinical sites and staff.

The fight against neglected diseases needs a reliable Sync & Share Solution

DNDi develops safe, effective, and - most importantly - affordable drugs for neglected diseases. These include sleeping sickness, Chagas disease, leishmaniasis, paediatric HIV, filaria diseases, mycetoma, and hepatitis C. A billion people worldwide – including 500 million children – are suffering from these diseases, that are responsible for 90 percent of the global burden of disease although the pharmaceutical market invests worldwide just more than ten percent of its research effort in this field.

DNDi operates globally through a number of private and public partnerships in more than 40 countries - including 50 public research centres and 20 pharmaceutical and biotech companies. DNDi supports health staff and doctors at several clinical research facilities with treatments and diagnostic tools.

Pascal Carpentier, DNDi Head of Information Systems and Technologies: „We use PowerFolder to collect microscope videos and photos taken in our hospitals in the Democratic Republic of the Congo, to find possible indications of an infection with the sleeping sickness“. It often involves large amounts of data, which must be sent as soon as possible, in a safe and especially reliable way. For Pascal Carpentier, PowerFolder is the best solution. „Our network is based on satellite links. PowerFolder - with its compression and block-transfer - allows us an extremely safe and cost-effective data transmission. Due to the high sensitivity of the patient data only a private cloud solution is possible. We are very pleased with PowerFolder. In future we will also plan to use it in Africa and Latin America.“

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) was established in Geneva in 2003 by renowned research and health organizations such as Doctors Without Borders (MSF) or the Institut Pasteur. The organization is active in research and development of affordable drugs for neglected diseases through partnerships with the public and private sectors (universities, research institutes, pharmaceutical companies, etc). DNDi aims to improve the quality of life and health of people suffering from these diseases - by an alternative model for drug development and by ensuring equal access to new and adapted therapies to patients in need. DNDi is funded by governments, private foundations, and individual donors.

About PowerFolder

The German company dal33t GmbH based in Meerbusch near Duesseldorf successfully develops and distributes its File Sync & Share Solution PowerFolder since 2007. The offer ranges from public, private and hybrid cloud solutions (EFSS). With high individualization options it optimally address customer needs. More than two million users worldwide, thousands of companies and most of the German universities use PowerFolder. PowerFolder users can access organization files from anywhere, collaborately edit them and share them with internal and external users - on any device. Safety and security is the top priority. The data is always encrypted and stored according to German data protection regulations on German servers or on premise. PowerFolder is promoted by the Federal Ministry of Economics and has been awarded the seal "IT Security Made in Germany".

Matthias Steinwachs
+49 2132 97922 98
press(at)powerfolder.com
http://www.powerfolder.com
PowerFolder
dal33t GmbH
Niederlöricker Str. 62
40667 Meerbusch
HRB 15833, Amtsgericht Neuss

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release DNDi: PowerFolder increases investment in E-Health here

News-ID: 330484 • Views:

More Releases from PowerFolder

For switchers: PowerFolder is offering a special deal for ownCloud users
For switchers: PowerFolder is offering a special deal for ownCloud users
The company dal33t GmbH, the firm behind PowerFolder, is offering a deal that makes the switch for ownCloud users that want to move to its German Sync & Share service even more attractive: just half price for the first year. To take advantage of this superb offer, anyone wishing to make the move simply has to produce evidence of an existing ownCloud user agreement. Meerbusch/Dusseldorf, 08.06.2016. - Owing to the events
ONLYOFFICE: PowerFolder with Document Editors in the Cloud
After a long test period PowerFolder - as the only German provider of cloud and Sync & Share solutions - offers now an integrated web-based document editor. For this purpose, the company from Meerbusch has integrated parts of the proven ONLYOFFICE. Meerbusch, April 28, 2016 - After a year of intense beta testing PowerFolder has completed the integration of the Document Server of ONLYOFFICE into its proven Sync & Share

More Releases for DNDi

AI Drug Development Platform Market CAGR 29.90% Future Outlook Led by Insilico M …
The AI Drug Development Platform market is experiencing significant growth, driven by the increasing need for efficient and cost-effective drug discovery processes. As the pharmaceutical industry faces mounting pressures to reduce development timelines and improve success rates, artificial intelligence is emerging as a transformative technology. By leveraging machine learning, data analytics, and natural language processing, AI platforms can analyze vast datasets, identify potential drug candidates, and optimize drug formulations at
Leishmaniasis - Pipeline Insight, 2025: Advancing Antiparasitic Innovation Amids …
Leishmaniasis, a neglected tropical disease caused by protozoan parasites of the genus Leishmania, remains a serious global health concern, especially in endemic regions across Asia, Africa, South America, and the Middle East. With high morbidity, limited treatment options, and growing resistance to traditional therapies like pentavalent antimonials, the need for novel, effective, and safer therapies has become more urgent than ever. DelveInsight's "Leishmaniasis - Pipeline Insight, 2025" profiles more than 3+
Pentavalent Antimonials Market Comprehensive Insight by Growth Rate, Industry St …
Pentavalent antimonials market is anticipated to grow at a significant CAGR during the forecast period. Pentavalent antimonials are a class of compounds used for the treatment of leishmaniasis. Antimonials have largely been used for the treatment of cutaneous and mucocutaneous leishmaniasis. These are widely available for use as an aqueous solution for intravenous or intramuscular use. Pentavalent antimonials are available as Sodium stibogluconate and meglumine antimoniate. Advances in existing anti-leishmanial
Global Pentavalent Antimonials Market Size, Share, Analysis, Industry Report and …
The global pentavalent antimonials market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Pentavalent antimonials are a class of compounds used for the treatment of leishmaniasis. Antimonials have largely been used for the treatment of cutaneous and mucocutaneous leishmaniasis. These are widely available for use as an aqueous solution for intravenous or intramuscular use. Pentavalent antimonials are available as Sodium stibogluconate and meglumine antimoniate. Advances
Amphotericin B Market Analysis and Forecast 2021: By Keyplayers Bristol-Myers Sq …
Global amphotericin B market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 12.00% in the above-mentioned forecast period. Download Free Sample Copy of Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-amphotericin-b-market&kavya Competitive Landscape and Global Amphotericin B Market Share Analysis: Bristol-Myers Squibb Company, MATINAS BIOPHARMA HOLDINGS, INC., Nano-X Imaging LTD., Nanomerics, DNDi, Abzena Ltd, Bharat Serums
Drug Addiction Treatment Market 2020-2025 | Top Key Players - Novartis, Indivior …
A market study "Global Drug Addiction Treatment Market" examines the performance of the Global Drug Addiction Treatment Market 2020. It encloses an in-depth Research of the Drug Addiction Treatment Market state and the competitive landscape globally. This report analyses the potential of Drug Addiction Treatment Market in the present and the future prospects from various angles in detail. Global Drug Addiction Treatment Market Overview: The report spread across 90 pages is an